Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Repligen Corporation to Present at Barclays Global Healthcare Conference

03/03/2021 | 07:30am EDT

WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST.

A live webcast of the discussion will be accessible through the Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com


Primary Logo


ę GlobeNewswire 2021
All news about REPLIGEN CORPORATION
05/05REPLIGENá : HC Wainwright Adjusts Repligen's Price Target to $240 From $225, Mai..
MT
05/04REPLIGENá : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
05/04REPLIGENá : Posts Rise in Q1 Adjusted Profit, Revenue; Amends 2021 Forecasts
MT
05/04REPLIGENá : Reported revenue was $142.8 million for the quarter, representing ye..
PU
05/04REPLIGEN CORPá : Results of Operations and Financial Condition, Financial Statem..
AQ
05/04REPLIGEN : Q1 Earnings Snapshot
AQ
05/04REPLIGENá : Earnings Flash (RGEN) REPLIGEN CORPORATION Posts Q1 Revenue $142.8M,..
MT
05/04REPLIGENá : Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q1 EPS $0.68, vs...
MT
05/04Repligen Reports First Quarter 2021 Financial Resultsáand Updates Full Year 2..
GL
04/20Repligen to Report First Quarter 2021 Financial Results
GL
More news
Financials (USD)
Sales 2021 585 M - -
Net income 2021 97,5 M - -
Net cash 2021 596 M - -
P/E ratio 2021 103x
Yield 2021 -
Capitalization 9 615 M 9 615 M -
EV / Sales 2021 15,4x
EV / Sales 2022 12,9x
Nbr of Employees -
Free-Float 91,7%
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 240,25 $
Last Close Price 175,13 $
Spread / Highest target 43,3%
Spread / Average Target 37,2%
Spread / Lowest Target 14,2%
EPS Revisions
Managers and Directors
NameTitle
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen T. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Senior Vice President-Global Operations & IT
Sector and Competitors
1st jan.Capitalization (M$)
REPLIGEN CORPORATION-8.61%9 615
ABBOTT LABORATORIES8.64%211 335
MEDTRONIC PLC8.16%171 070
BECTON, DICKINSON AND COMPANY-1.43%71 725
HOYA CORPORATION-7.88%44 625
ALIGN TECHNOLOGY, INC.3.77%43 881